Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II postoperative radiochemotherapy plus cetuximab in high-risk head and neck squamous cell carcinoma
2007-004384-22Phase 2Completed
- Sponsor
- Centre Antoine Lacassagne
- Start
- Aug 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), Oral Mucosal Carcinoma, oropharyngeal squamous cell carcinoma (OPSCC) and 2 more, sponsored by Centre Antoine Lacassagne. Primary endpoint: 2-year recurrence-free survival. Started Aug 2010; status: completed.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Oral Mucosal Carcinomaoropharyngeal squamous cell carcinoma (OPSCC)squamous cell carcinoma of the hypopharynxlaryngeal squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on 2007-004384-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004384-22.